Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells

Anti-Cancer Drugs

Volumn 23, Issue 6, 2012, Pages 627-637

  Magan, Natisha ^a   Isaacs, Richard J ^b   Stowell, Kathryn M ^a  

^a MASSEY UNIVERSITY   (New Zealand)

^b Regional Cancer Treatment Service   (New Zealand)

Author keywords

chemotherapy; doxorubicin; nuclear factor Y; poly (ADP ribose) polymerase; ribosylation; specificity factor 1; topoisomerase; transcriptional regulation

Indexed keywords

DNA TOPOISOMERASE; DOXORUBICIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; PROTEIN TOPOISOMERASE II ALPHA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; BINDING AFFINITY; CELL DEATH; DRUG POTENTIATION; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY SEQUENCE;

ANTIGENS, NEOPLASM; CELL DEATH; DNA; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR;

EID: 84861799916     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328350900f     Document Type: Article

References (54)

1. Roca J. Topoisomerase II: a fitted mechanism for the chromatin landscape. Nucleic Acids Res 2009; 37:721-730.
2. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 2009; 37:738-748.
3. Mirski SE, Bielawski JC, Cole SP. Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta. Biochem Biophys Res Commun 2003; 306:905-911.
4. Sakaguchi A, Kikuchi A. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. J Cell Sci 2004; 117:1047-1054.
5. Linka RM, Porter AC, Volkov A, Mielke C, Boege F, Christensen MO. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Res 2007; 35:3810-3822.
6. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000; 64:221-253.
7. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003; 99:167-181.
8. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8:1061-1067.
9. Kellner U, Rudolph P, Parwaresch R. Human DNA-topoisomerases-diagnostic and therapeutic implications for Cancer. Onkologie 2000; 23:424-430.
10. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 2008; 105:9053-9058.
11. Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004; 24:201-209.
12. Uesaka T, Shono T, Kuga D, Suzuki SO, Niiro H, Miyamoto K, et al. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol 2007; 84:119-129.
13. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009; 101:644-650.
14. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54:357-361.
15. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 2001; 35:161-204.
16. Saxena D, Yiu GK, Ni X, Huang KC, Mantovani R, Jacquemin-Sablon AG, et al. Characterization of promoter elements involved in the down-regulation of topoIIa expression in a drug-resistant cell line. Gene 2004; 342: 145-155.
17. Wielckens K, George E, Pless T, Hilz H. Stimulation of poly(ADP-ribosyl)ation during Ehrlich ascites tumor cell starvation and suppression of concomitant DNA fragmentation by benzamide. J Biol Chem 1983; 258:4098-4104.
18. Alvarez-Gonzalez R, Althaus FR. Poly(ADP-ribose) catabolism in mammalian cells exposed to DNA-damaging agents. Mutat Res 1989; 218:67-74.
19. Gagne JP, Hendzel MJ, Droit A, Poirier GG. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr Opin Cell Biol 2006; 18:145-151.
20. Heeres JT, Hergenrother PJ. Poly(ADP-ribose) makes a date with death. Curr Opin Chem Biol 2007; 11:644-653.
21. Mendoza-Alvarez H, Alvarez-Gonzalez R. Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J Biol Chem 1993; 268:22575-22580.
22. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999; 342: 249-268.
23. Gagné J, Isabelle M, Lo KS, Bourassa S, Hendzel MJ, Dawson VL, et al. Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucl Acids Res 2008; 36:6959-6976.
24. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10:293-301.
25. Cosi C. New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets. Expert Opin Ther Patents 2002; 12:1047-1071.
26. Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, Scarsella M, et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 2007; 43:2124-2133.
27. D'Onofrio G, Tramontano F, Dorio AS, Muzi A, Maselli V, Fulgione D, et al. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. Biochem Pharmacol 2011; 2:194-202.
28. Pacher P, Liaudet L, Bai P,Virag L, Mabley JG, Hasko G, Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002; 300:862-867.
29. Curtin NJ. PARP inhibitors for cancer therapy. Expert rev Mol Med 2005; 7:15.
30. De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, et al. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2006; 2:179-185.
31. Hochhauser D, Stanway CA, Harris AL, Hickson ID. Cloning and characterization of the 5-flanking region of the human topoisomerase II alpha gene. J Biol Chem 1992; 267:18961-18965.
32. Isaacs RJ, Harris AL, Hickson ID. Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells. J Biol Chem 1996; 271:16741-16747.
33. Magan N, Szremska AP, Isaacs RJ, Stowell KM. Modulation of DNA topoisomerase II alpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factors. Biochem J 2003; 374:723-729.
34. Joshi AA, Wu Z, Reed RF, Suttle DP. Nuclear factor-Y binding to the topoisomerase IIalpha promoter is inhibited by both the p53 tumor suppressor and anticancer drugs. Mol Pharmacol 2003; 63:359-367.
35. Bronner C, Hopfner R, Mousli M. Transcriptional regulation of the human topoisomerase IIalpha gene. Anticancer Res 2003; 22:605-612.
36. Allen KA, Williams AO, Isaacs RJ, Stowell KM. Down-regulation of human topoisomerase IIalpha correlates with altered expression of transcriptional regulators NF-YA and Sp1. Anticancer Drugs 2004; 15:357-362.
37. Williams AO, Isaacs RJ, Stowell KM. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions. BMC Mol Biol 2007; 8:36.
38. Liang SG, Maity SN. Pathway of complex formation between DNA and three subunits of CBF/NF-Y. Photocross-linking analysis of DNA-protein interaction and characterization of equilibrium steps of subunit interaction and DNA binding. J Biol Chem 1998; 273:31590-31598.
39. Atienza JM, Yu N, Kirstein SL, Xi B, Wang X, Xu X, et al. Dynamic and label-free cell based assays using the real-time electronic sensing system. Assay Drug Dev Technol 2006; 5:597-607.
40. Kubo T, Kohno K, Ohga T, Taniguchi K, Kawanami K, Wada M, et al. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res 1995; 55:3860-3864.
41. Tuteja R, Tuteja N. Ku autoantigen: a multifunctional DNA-binding protein. Crit Rev Biochem Mol Biol 2000; 35:1-33.
42. Rouleau M, Aubin RA, Poirier GG. Poly(ADP-ribosyl)ated chromatin domains: access granted. J Cell Sci 2004; 117:815-825.
43. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: PAR-laying NAD+ into a nuclear signal. Genes Dev 2005; 19:1951-1967.
44. Zaniolo K, Desnoyers S, Leclerc S, Guerin SL. Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1. BMC Mol Biol 2007; 8:96.
45. Luo HR, Hattori H, Hossain MA, Hester L, Huang Y, Lee-Kwon W, et al. Akt as a mediator of cell death. Proc Natl Acad Sci USA 2003; 100: 11712-11717.
46. Xiao C, Lachance B, Sunahara G, Luong JH. An in depth analysis of electrical cell-substrate impedance sensing to study the attachment and spreading of mammalian cells. Anal Chem 2002; 74:1333-1339.
47. Atienza JM, Zhu J, Wang X, Xu X, Abassi Y. Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 2005; 10:795-805.
48. Atienzar FA, Tilmant K, Gerets HH, Toussaint G, Speeckaert S, Hanon E, et al. The use of real-time cell analyzer technology in drug discovery: defining optimal cell culture conditions and assay reproducibility with different adherent cellular models. J Biomol Screen 2011; 16:575-587.
49. Lu DY, Huang M, Xu CH, Yang WY, Hu CX, Lin LP, et al. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol 2005; 5:11.
50. Draganov AB. Novel rhein analogues a potential anticancer agents and a novel metal free synthesis of 6H-isoindol[2,1-Aindol-6-one. Chem Thesis 2011 Paper 40.
51. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 1996; 319:307-313.
52. Kadonaga JT, Jones KA, Tjian R. Promoter-specific activation of RNA polymerase II transcription by Sp1. Trends Biochem Sci 1986; 11:20-23.
53. Coustry F, Hu Q, de Crombrugghe B, Maity SN. CBF/NF-Y functions both in nucleosomal disruption and transcription activation of the chromatin-assembled topoisomerase IIalpha promoter. Transcription activation by CBF/NF-Y in chromatin is dependent on the promoter structure. J Biol Chem 2001; 276:40621-40630.
54. Peralta-Leal A, Rodŕiguez-Vargas JM, Aguilar-Quesada R, Rodŕiguez MI, Linares JL, de Almodóvar MR, et al. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 2009; 47:13-26.